Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living‐donor liver transplantation

Cholestatic hepatitis C is one of the most serious but still unaddressed disorders after liver transplantation.

[1]  R. Fontana,et al.  Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  Y. Maehara,et al.  Primary Graft Dysfunction After Living Donor Liver Transplantation Is Characterized by Delayed Functional Hyperbilirubinemia , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  R. Lopez,et al.  Interleukin‐28B polymorphisms are associated with fibrosing cholestatic hepatitis in recurrent hepatitis C after liver transplantation , 2012, Clinical transplantation.

[4]  K. Pfeiffer,et al.  Early viral load and recipient interleukin‐28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  R. Fontana,et al.  of Successful Peginterferon , Ribavirin , and Daclatasvir therapy for Recurrent Cholestatic Hepatitis C following Liver Retransplantation , 2012 .

[6]  D. Samuel,et al.  Fibrosing Cholestatic Hepatitis in HIV/HCV Co‐Infected Transplant Patients—Usefulness of Early Markers After Liver Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  D. Samuel,et al.  Significance of isolated hepatic veno‐occlusive disease/sinusoidal obstruction syndrome after liver transplantation , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[8]  T. Schiano,et al.  Clinical characterization of patients developing histologically‐proven fibrosing cholestatic hepatitis C post‐liver transplantation , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  S. Kulkarni,et al.  Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. , 2011, Transplantation proceedings.

[10]  Y. Maehara,et al.  De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: Report of a case , 2011, Surgery Today.

[11]  Y. Maehara,et al.  Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. , 2010, Gastroenterology.

[12]  M. Russo,et al.  Post–liver transplant cholestatic hepatitis C: A systematic review of clinical and pathological findings and application of consensus criteria , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[13]  K. Shirabe,et al.  Living donor hepatectomies with procedures to prevent biliary complications. , 2010, Journal of the American College of Surgeons.

[14]  K. Horimoto,et al.  Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. , 2010, Gastroenterology.

[15]  Y. Maehara,et al.  Rituximab, IVIG, and Plasma Exchange Without Graft Local Infusion Treatment: A New Protocol in ABO Incompatible Living Donor Liver Transplantation , 2009, Transplantation.

[16]  G. McCaughan,et al.  Early high peak hepatitis C viral load levels independently predict hepatitis C–related liver failure post–liver transplantation , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[17]  Y. Maehara,et al.  Bloodless splenectomy during liver transplantation for terminal liver diseases with portal hypertension. , 2009, Journal of the American College of Surgeons.

[18]  A. Krasinskas,et al.  The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  Y. Maehara,et al.  Explanted Portal Vein Grafts for Middle Hepatic Vein Tributaries in Living-Donor Liver Transplantation , 2007, Transplantation.

[20]  J. Pomposelli,et al.  Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. , 2007, Human pathology.

[21]  Y. Maehara,et al.  Biliary strictures in living donor liver transplantation: Incidence, management, and technical evolution , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[22]  K. Agarwal,et al.  Immunohistochemical assessment of hepatitis C virus antigen in cholestatic hepatitis after liver transplantation , 2006, Journal of Clinical Pathology.

[23]  T. Starzl,et al.  Immunosuppression for liver transplantation in HCV‐infected patients: Mechanism‐based principles , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  G. Klintmalm,et al.  Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation. , 2004, The Journal of infectious diseases.

[25]  S. Cheung,et al.  Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: Successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  R. Wiesner,et al.  Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on Liver Transplantation and Hepatitis C , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[27]  M. Berenguer,et al.  Natural history of recurrent hepatitis C , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[28]  Dorothy M. Lang,et al.  Evolution of hepatitis C viral quasispecies after liver transplantation. , 2001, Gastroenterology.

[29]  J. Takamatsu,et al.  Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. , 1997, Journal of hepatology.